USA: The Launch Place has announced its $250,000 investment in Revibe Technologies, a North Carolina-based startup developing digital therapy software for wearables to treat attention-deficit/hyperactivity disorder (ADHD) and autism. After bringing its flagship artificial intelligence-driven smartwatch and wristband to the adolescent market, the company is iterating on its success with FokusRx—a nonpharmacologic software-as-a-medical device (SaMD) approach to treating attention and focus deficits.

Healthtech startup, Virtue Health Group Limited (Virtue), has secured £1 million in seed funding in an investment round led by the Midlands Engine Investment Fun (MEIF) managed by Midven, part of the Future Planet Capital Group. The company has secured £500,000 from the MEIF as well as further investments from QVentures and a number of business angels.

Hearing Diagnostics, the Edinburgh-based healthtech company, is eyeing commercialisation in the domestic and US markets following a £1.1m fundraise.

Led by Archangels, the world’s longest continually running angel investment syndicate, the funding will unlock the spatial hearing screening technology’s market potential. Other funders in the raise include Scottish Enterprise through its Scottish Co-Investment Fund.

London-based Period care and sexual health brand Here We Flo has raised £1.7m in an angel funding round, supported by Angel Investment Network, the world’s largest online angel investment platform. 

Here We Flo’s mission is ‘shamelessly natural care for life’s messiest moments’. The brand intends to challenge, shame and disrupt the period, bladder and sexual wellness markets with organic and vegan products. 

Every material is sourced with sustainability in mind and free of any dyes, pesticides, petroleum plastics and other contaminants that may impact health. The product list includes FLO Period Care, glo Sensitive Bladder Care and XO! Sexual Wellness.

University of Birmingham spinout ChromaTwist Ltd has secured £487k of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market.

This second round of equity investment, which brought in funds from Directors, existing Angel investors, angelgroups and the University of Birmingham will allow the company to continue product development with industry partners, and enable rapid development of products for market entry as soon as 2023. 

Mid Atlantic Bio Angels Group (MABA) has made an investment in The Shape Sensing Company (TSSC).

A company based at Queen’s University, Belfast which has developed a potentially life-saving new cancer treatment is to invest almost £8m to take its first anti-cancer drug through a first-in-human, Phase 1a clinical trial and perform further scientific development work.

UK-based gynaecological health startup Daye, which is known for having invented the CBD tampon that is now used by over 60,000 women in the UK, has completed a £10 million funding round. The company’s successful Series A funding round includes investment from London-based Hambro Perks, an international investment firm which focuses on breakthrough and growth technology companies and included angel funding from investors including Dr Michelle Tempest, Dr Fiona Pathiraja and Martin Varsavsky, founder of Prelude, the largest chain of fertility clinics in the world.

Award winning, early stage Healthtech company, BlueSkeye AI Ltd, has secured £3.4m in funding to pursue its mission to improve people’s quality of life through the use of its proprietary face and voice analysis technology. The round was led by XTX Ventures, which invested alongside Foresight Group (through The Midlands Engine Investment Fund), Praetura Ventures (through Praetura’s GMC Life Sciences Fund), the University of Nottingham and a consortium of high-net-worth individuals.

Oxford Medical Simulation (OMS), a provider of highly realistic virtual reality healthcare training, has raised a further £2.1 million in a funding round that included ACF Investors and angel investor Dr Nicolaus Henke, former chairman of Quantum Black and former head of McKinsey’s global healthcare practice.

A Nottingham company which has devised a blood test that could revolutionise management of tuberculosis (TB) has raised a further £2.4m to further develop the test and support clinical trials.

Enhanc3D Genomics, a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – GenLink3D [TM]. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures.